AGENDA MONDAY SEPTEMBER 26

Transcription

1 SEPTEMBER 26-29

2 AGENDA MONDAY SEPTEMBER 26 12:00 pm REGISTRATION DESK OPENS 12:00 pm LUNCH PEPTIDE SHOWCASE 12:30 pm Chairpersons Welcome Chris Rhodes, Chair Scientific Advisory Board, BPS 1:00 pm ARTERY Therapeutics, Inc. Jan Johansson, CEO and Founder 1:20 pm University of Western Ontario Len Luyt, Associate Professor 1:40 pm CDG Therapeutics Inc Craig Beattie, CSO 2:00 pm Intarcia Therapeutics Scott Peterson, Executive Director, Business Development 2:20 pm Neon Therapeutics Jesse Z. Dong, Vice President, Peptide Chemistry 2:40 pm BREAK 3:00 pm NovaBiotics Ltd Deborah O'Neil, CEO/CSO 3:20 pm Reflexion Pharmaceuticals Dana Ault-Riche, CEO 3:40 pm SYNG Pharmaceuticals Inc Vinay Singh, Founder & CEO 4:00 pm Cupid Peptides Jonathan Ryves, Chief Executive Officer 4:30 pm NETWORKING RECEPTION AND PARTNERING WITH 1-1 MEETINGS

3 AGENDA TUESDAY SEPTEMBER 27 8:00 am BREAKFAST PEPTIDE SHOWCASE 9:20 am ProteoThera, Inc. Parth Patwari, CSO 9:40 am Cogentis Therapeutics Yvonne Angell, Scientific Consultant 10:00 am BREAK PEPTIDES IN THE CLINIC 10:20 am 11:00 am 11:40 am Rhythm Pharmaceuticals Lex Van der Ploeg, CSO Setmelanotide for the treatment of rare forms of monogenic obesity Novo Nordisk A/S Jesper Lau, vice president Design of Long-acting GLP-1 Analogs Applicable for Once Weekly and Oral Dosing Tarsa Therapeutics James Gilligan, Chief Scientific Officer Product Development of TBRIAâ, the first oral salmon calcitonin product for the treatment and prevention of post-menopausal osteoporosis 12:20 pm LUNCH 1:20 pm 2:00 pm Cara Therapeutics, Inc. Stephen O'Connor, Senior Director, Chemistry Research and CMC CR845, A Novel Peripherally Acting Kappa Opioid Receptor Agonist for the Treatment of Pain and Pruritus Apellis Pharmaceuticals Carolina Vega, Director of Pharmaceutical Development APL-2 and complement inhibition; a potential treatment of PNH and other complement complement-mediated diseases 2:40 pm Arrowhead Pharmaceuticals Aaron Almeida, Senior Scientist II Dynamic PolyConjugates for targeted in vivo delivery of sirna 3:30 pm POSTER SESSION AND PARTNERING with 1-1 MEETINGS YOUNG INVESTIGATOR AWARD PRESENTATION 5:40 pm University of North Carolina at Chapel Hill Albert Bowers, Professor Chemoenzymatic Platforms for the Discovery of New Peptide Therapeutics 7:00 pm GALA DINNER

4 AGENDA WEDNESDAY SEPTEMBER 28 8:30 am BREAKFAST DRUG DELIVERY 9:30 am 10:10 am California Institute for Biomedical Research Weijun Shen, Principal Investigator A Peptide Engineering Platform for Generating Stapled Long-acting Peptide Hormones Eli Lilly and Company Adam Mezo, Sr. Research Advisor, Group Leader Comparison of select peptide time-extension technologies in the context of a GIP/GLP-1- based dual-agonist peptide 10:50 am BREAK 11:10 am 11:50 am University of Utah Danny Chou, Assistant Professor Bio-inspired protein engineering for ultrafast-acting insulin The University of Arizona Robin Polt, Professor of Chemistry & Biochemistry, BIO5 Biousian Glycopeptides Penetrate the BBB to Function as CNS Drugs 12:30 pm LUNCH Matteo Villian Moderator 1:30 pm PANELISTS Daniel Samson Chris Holmes Jesper Lau 1:30 pm PARTNERING with 1-1 MEETINGS 3:30 pm BREAK 3:45 pm SPONSORED PRESENTATION Solid Form Solutions

5 AGENDA THURSDAY SEPTEMBER 29 8:30 am BREAKFAST ADVANCES IN CHEMISTRY AND ANALYTICS SESSION SPONSORED BY 9:30 am Novo Nordisk Fa Liu, Director of Chemistry Novel Synthetic Strategies for Insulin and Related Peptides 10:10 am AmideBio Michael Stowell, CTO Rapid-Recombinant SAR of Conformation Locked Insulin Analogs 10:50 am BREAK 11:05 am Purdue University Jean Chmielewski, Distinguished Professor of Chemistry Targeting Intracellular Pathogenic Bacteria with Unnatural Proline-Rich Peptides: Coupling Antibacterial Activity with Macrophage Penetration 11:45 am Allosterix Pharmaceuticals, LLC Greg Czyryca, President Synthetic Biochemistry - Peptides via De Novo Design. Case Study - Modulation of HIV Envelope Protein gp :30 pm LUNCH

6 SPONSORS